Almandil, NB, Liu, Y, Murray, ML et al (2013) Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis. Paediatic Drugs, 15: 139–50.
Altamura, AC, Moro, AR, Percudani, M (1994) Clinical pharmacokinetics of fluoxetine. Clinical Pharmacokinetics, 26: 201–14.
Aman, MG, Smith, T, Arnold, LE et al (2014) A review of atomoxetine effects in young people with developmental disabilities. Research in Developmental Disabilities, 35: 1412–24.
American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). APA.
Arnold, LE, Aman, MG, Cook, AM et al (2006) Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. Journal of the American Academy of Child and Adolescent Psychiatry, 45: 1196–205.
Auyeung, B, Lombardo, MV, Heinrichs, M et al (2015) Oxytocin increases eye contact during a real-time, naturalistic social interaction in males with and without autism. Translational Psychiatry, 5: e507.
Bobo, WV, Cooper, WO, Stein, CM et al (2013) Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry, 70: 1067–75.
Brent, J (2013) Commentary on the abuse of metal chelation therapy in patients with autism spectrum disorders. Journal of Medical Toxicology, 9: 370–2.
Buitelaar, JK, van der Gaag, RJ, van der Hoeven, J (1998) Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: results of an open-label study. Journal of Clinical Psychiatry, 59: 56–9.
Ching, H, Pringsheim, T (2012) Aripiprazole for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews, 5: CD009043.
Coghill, D, Banaschewski, T, Lecendreux, M et al (2013) European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. European Neuropsychopharmacology, 23: 1208–18.
Dominick, K, Wink, LK, McDougle, CJ et al (2015) A retrospective naturalistic study of ziprasidone for irritability in youth with autism spectrum disorder. Journal of Child and Adolescent Psychopharmacology, 25: 397-401.
Elchaar, GM, Maisch, NM, Augusto, LM (2006) Efficacy and safety of naltrexone use in pediatric patients with autistic disorder. Annals of Pharmacotherapy, 40: 1086–95.
Fankhauser, MP, Karumanchi, VC, German, ML et al (1992) A double blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. Journal of Clinical Psychiatry, 53: 77-82.
Findling, RL, Mankoski, R, Timko, K et al (2014) A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry, 75: 22-30.
Ghanizadeh, A, Sahraeizadeh, A, Berk, M (2014) A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiatry and Human Development, 45: 185–92.
Gobbi, G, Pulvirenti, L (2001) Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behaviour. Journal of Psychiatry & Neuroscience, 26: 340–1.
Golubchik, P, Sever, J, Weizman, A (2011) Low-dose quetiapine for adolescents with autistic spectrum disorder and aggressive behavior: open-label trial. Clinical Neuropharmacology, 34: 216–9.
Gringras, P, Gamble, C, Jones, AP et al (2012) Melatonin for sleep problems in children with neurodevelopmental disorders: randomised double masked placebo controlled trial. BMJ, 345: e6664.
Guastella, AJ, Gray, KM, Rinehart, NJ et al (2015) The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial. Journal of Child Psychology and Psychiatry, 56: 444–52.
Hardan, AY, Jou, RJ, Handen, BL (2005) Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders. Journal of Autism Development Disorders, 35: 387–91.
Hardan, AY, Fung, LK, Libove, RA et al (2012) A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biological Psychiatry, 71: 956–61.
Harfterkamp, M, van de Loo-Neus, G, Minderaa, RB et al (2012) A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 51: 733–41.
Harfterkamp, M, Buitelaar, JK, Minderaa, RB et al (2014) Atomoxetine in autism spectrum disorder: no effects on social functioning; some beneficial effects on stereotyped behaviors, inappropriate speech, and fear of change. Journal of Child and Adolescent Psychopharmacology, 24: 481–5.
Harfterkamp, M, van der Meer, D, van der Loo-Neus, G et al (2015) No evidence for predictors of response to atomoxetine treatment of attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder. Journal of Child and Adolescent Psychopharmacology, 25: 372–5.
Hazell, P (2007) Drug therapy for attention-deficit/hyperactivity disorderlike symptoms in autistic disorder. Journal of Paediatrics and Child Health, 43: 19-24.
Hill, AP, Zuckerman, K, Fombonne, E (2014) Epidemiology of autism spectrum disorders. In Handbook of Autism and Pervasive Developmental Disorders (4th edn) (eds Volkmar, FR, Paul, R, Rogers, SJ et al): 57-96. Wiley.
Hollander, E, Wasserman, S, Swanson, EN et al (2006a) A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. Journal of Child and Adolescent Psychopharmacology, 16: 541–8.
Hollander, E, Soorya, L, Wasserman, S et al (2006b) Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. International Journal of Neuropsychopharmacology, 9: 209–13.
Hollander, E, Chaplin, W, Soorya, L et al (2010) Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology, 35: 990–8.
Jahromi, LB, Kasari, CL, McCracken, JT et al (2009) Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. Journal of Autism and Developmental Disorders, 39: 395-404.
Jesner, OS, Aref-Adib, M, Coren, E (2007) Risperidone for autism spectrum disorder. Cochrane Database of Systematic Reviews, 1: CD005040.
Khwaja, OS, Ho, E, Barnes, KV et al (2014) Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. Proceedings of the National Academy of Sciences of the United States of America, 111: 4596–601.
Lee, YJ, Oh, SH, Park, C et al (2014) Advanced pharmacotherapy evidenced by pathogenesis of autism spectrum disorder. Clinical Psychopharmacology and Neuroscience, 12: 19-30.
Levy, SE, Hyman, SL (2008) Complementary and alternative medicine treatments for children with autism spectrum disorders. Child and Adolescent Psychiatric Clinics of North America, 17: 803–20.
Marcus, RN, Owen, R, Kamen, L et al (2009) A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 48: 1110–9.
McCracken, JT, McGough, J, Shah, B et al (2002) Risperidone in children with autism and serious behavioural problems. New England Journal of Medicine, 347: 314–21.
McDougle, CJ, Scahill, L, Aman, MG et al (2005) Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. American Journal of Psychiatry, 162: 1142–8.
Mills, JL, Hediger, ML, Molloy, CA et al (2007) Elevated levels of growth-related hormones in autism and autism spectrum disorder. Clinical Endocrinology (Oxford), 67: 230–7.
Nagaraj, R, Singhi, P, Malhi, P (2006) Risperidone in children with autism: randomized, placebo-controlled, double-blind study. Journal of Child Neurology, 21: 450–5.
Narayanan, A, White, CA, Saklayen, S et al (2010) Effect of propranolol on functional connectivity in autism spectrum disorder – a pilot study. Brain Imaging and Behaviour, 4: 189–97.
National Institute for Health and Care Excellence (2011) Autism Diagnosis in Children and Young People: Recognition, Referral and Diagnosis of Children and Young People on the Autism Spectrum (Clinical Guideline GG128). NICE.
National Institute for Health and Care Excellence (2013) Autism: The Management and Support of Children and Young People on the Autism Spectrum (Clinical Guideline GG170). NICE.
Newcomer, JW (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs, 19 (suppl 1): 1-93.
Nikoo, M, Radnia, H, Farokhnia, M et al (2015) N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety. Clinical Neuropharmacology, 38: 11–7.
Owen, R, Sikich, L, Marcus, RN et al (2009) Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics, 124: 1533–40.
Posey, DJ, Kem, DL, Swiezy, NB et al (2004) A pilot study of D-cycloserine in subjects with autistic disorder. American Journal of Psychiatry, 161: 2115–7.
Rossignol, DA, Frye, RE (2011) Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Developmental Medicine and Child Neurology, 53: 783–92.
Sandin, S, Lichtenstein, P, Kuja-Halkola, R et al (2014) The familial risk of autism. JAMA, 311: 1770–7.
Santosh, PJ, Baird, G, Pityaratstian, N et al (2006) Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study. Child: Care, Health and Development, 32: 575–83.
Santosh, PJ, Colonneli, C (2012) Co-occurrence of attention deficit hyperactivity disorder (ADHD) and autism spectrum disorders (ASD). Cutting Edge Psychiatry in Practice, 2: 118–26.
Santosh, PJ (2014) Medication in autism spectrum disorder. Cutting Edge Psychiatry in Practice, 4: 143–55.
Scahill, L, Aman, MG, McDougle, CJ et al (2006) A prospective open trial of guanfacine in children with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 16: 589–98.
Scahill, L, Hallett, V, Aman, MG et al (2013) Brief Report: social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials. Journal of Autism and Developmental Disorders, 43: 739–46.
Scahill, L, McCracken, JT, King, BH et al (2015) Extended-release guanfacine for hyperactivity in children with autism spectrum disorder. American Journal of Psychiatry, 172: 1197–206.
Schade, S, Paulus, W (2015) D-cycloserine in neuropsychiatric diseases: a systematic review. International Journal of Neuropsychopharmacology, 12 Sept: doi 10.1093/ijnp/pyv102 [Epub ahead of print].
Simonoff, E, Pickles, A, Charman, T et al (2008) Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. Journal of the American Academy of Child and Adolescent Psychiatry, 47: 921–9.
Simonoff, E, Taylor, E, Baird, G et al (2013) Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability. Journal of Child Psychology and Psychiatry, 54: 527–35.
Singh, K, Connors, SL, Macklin, EA et al (2014) Sulforaphane treatment of autism spectrum disorder (ASD). Proceedings of the National Academy of Sciences of the United States of America, 111: 15550–5.
Sukhodolsky, DG, Bloch, MH, Panza, KE et al (2013) Cognitive-behavioural therapy for anxiety in children with high-functioning autism: a meta-analysis. Pediatrics
Urbano, M, Okwara, L, Manser, P et al (2014) A trial of D-cycloserine to treat stereotypies in older adolescents and young adults with autism spectrum disorder. Clinical Neuropharmacology, 37: 69-72.
Urbano, M, Okwara, L, Manser, P et al (2015) A trial of d-cycloserine to treat the social deficit in older adolescents and young adults with autism spectrum disorders. Journal of Neuropsychiatry and Clinical Neurosciences, 27: 133–8.
Voelker, R (2010) FDA warning targets OTC chelation products. JAMA, 304: 2112.
Walker, WC, Murdoch, JM (1957) Cycloserine in the treatment of pulmonary tuberculosis: a report on toxicity. Tubercle, 38: 297-302.
Walkup, JT, Albano, AM, Piacentini, J et al (2008) Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. New England Journal of Medicine, 359: 2753–66.
Wermter, AK, Kamp-Becker, I, Hesse, P (2010) Evidence for the involvement of genetic variation in the oxytocin receptor gene (OXTR) in the etiology of autistic disorders on high-functioning level. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, 153B: 629–39.
Willemsen-Swinkels, SH, Buitelaar, JK, Nijhof, GJ et al (1995) Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults. Double-blind placebo-controlled studies. Archives of General Psychiatry, 52: 766–73.
Williams, K, Marraffa, C (2012) No evidence yet to support omega-3 fatty acids as a treatment for autism. Journal of Paediatrics and Child Health, 48: 534–6.
Williams, K, Brignell, A, Randall, M et al (2013) Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews, 8: CD004677.
Zuddas, A, Ledda, MG, Fratta, A et al (1996) Clinical effects of clozapine on autistic disorder. American Journal of Psychiatry, 153: 738.